NCT00472693

Bevacizumab and Abraxane as Second-line Therapy in Triple Negative Metastatic Breast Cancer

A Phase II Trial of Bevacizumab and ABI-007 (Abraxane) as Second-line Therapy in Her-2 Negative, Hormone Receptor Negative Metastatic Breast Cancer

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 5 (actual)
• Sponsor: Abramson Cancer Center at Penn Medicine · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether the addition of bevacizumab to Abraxane as second-line therapy in Her-2 negative, hormone receptor negative metastatic breast cancer.

Conditions

• Breast Cancer

Interventions

Type	Name	Description
DRUG	Bevacizumab, Abraxane	Bevacizumab, 10 mg/m2 IV days 1 and 15; ABI-007, 100 mg/m2 IV days 1, 8, 15 of each 28 day cycle. Continue treatment until disease progression, patient withdrawal or unacceptable toxicities.

Timeline

• Start date: 2007-05-01
• Primary completion: 2011-04-01
• Completion: 2011-04-01
• First posted: 2007-05-14
• Last updated: 2020-04-09

Locations

1 site across 1 country: United States